Financial Contrast: Envista (NYSE:NVST) & Stagezero Life Sciences (OTCMKTS:SZLSF)

Envista (NYSE:NVST) and Stagezero Life Sciences (OTCMKTS:SZLSF) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.

Volatility & Risk

Envista has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, Stagezero Life Sciences has a beta of -4.43, suggesting that its stock price is 543% less volatile than the S&P 500.

Earnings & Valuation

This table compares Envista and Stagezero Life Sciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.72 billion	1.60	$47.00 million	$0.28	95.41
Stagezero Life Sciences	N/A	N/A	N/A	($0.01)	-0.51

Envista has higher revenue and earnings than Stagezero Life Sciences. Stagezero Life Sciences is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Envista and Stagezero Life Sciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	0	9	7	0	2.44
Stagezero Life Sciences	0	0	0	0	0.00

Envista presently has a consensus target price of $27.85, indicating a potential upside of 4.24%. Given Envista’s stronger consensus rating and higher possible upside, equities analysts plainly believe Envista is more favorable than Stagezero Life Sciences.

Profitability

This table compares Envista and Stagezero Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Envista	1.73%	6.54%	3.60%
Stagezero Life Sciences	N/A	N/A	N/A

Summary

Envista beats Stagezero Life Sciences on 10 of the 10 factors compared between the two stocks.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

About Stagezero Life Sciences

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company’s lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman’s risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.